Eric Grigsby, MD, MBA, Joins Bioness as Chief Medical Officer

Valencia, Calif-headquartered Bioness welcomes Eric Grigsby, MD, MBA, as its new chief medical officer.

The company notes in a media release that Grigsby’s experience with pain management will be of particular significance toward advancing Bioness’ recently launched StimRouter Neuromodulation System, a minimally invasive device specifically designed to treat chronic peripheral pain. This new role will also complement his position as chief medical officer at the Alfred Mann Foundation.

Grigsby has more than 25 years of experience in pain management, founding the Napa Pain Institute in 1992 and continuing to practice there as a board-certified pain physician. He is also the former president and chief executive officer of Neurovations, a leading clinical trial management and pain education consulting company, per the release.

Grigsby graduated from Boston University Medical School in 1984 and then trained in General Surgery, Anesthesiology and Pain Management at the Mayo Clinic in Rochester, Minnesota. He later joined the Medical Staff of Mayo Medical School and was the founding medical director of the first pain management center at University of California, Davis Medical Center.

“We are thrilled to welcome Dr Grigsby to Bioness as we continue to ramp our efforts around the StimRouter,” says Todd Cushman, chief executive officer of Bioness, in the release. “Dr Grigsby brings a wealth of clinical experience in pain management and has helped develop surgical implants specific to neuromodulation.”

“I am excited to join the Bioness team to help advance our innovations in neuromodulation to aid clinicians and patients better manage chronic pain,” Grigsby shares. “While working with the Alfred Mann Foundation, I saw firsthand the passion and drive needed to bring novel products that meet unmet medical needs to market. The StimRouter embodies Alfred Mann’s vision of improving the lives of people in need through disruptive technology, and I am excited to help Bioness achieve that mission with this new device.”

[Source: Bioness]